Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

ines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the further development of MAP0005 and the potential application of MAP Pharmaceuticals' technologies to additional product candidates. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and commercialization of product candidates incorporating MAP Pharmaceuticals' technologies. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10K, filed with the SEC on March 20, 2008, available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... total revenues of $39.8 million for the second quarter ... of $24.5 million for the second quarter of 2013. ... sold on May 30, 2014, has been accounted for ... been excluded from continuing operations for all periods. ...
(Date:7/29/2014)... July 29, 2014 Pfenex Inc. (NYSE MKT: PFNX) ... public offering of 8,333,333 shares of its common  stock at ... of the common stock was offered by Pfenex. In addition, ... up to 1,250,000 additional shares of common stock at the ... traded on the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Pfenex Announces Closing of Initial Public Offering 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... 2011 A west coast secret is finally reaching the ... from Beverly Hills, California, a health and beauty boutique named ... ).  A clinically tested dietary supplement is helping thousands of ... than 4 weeks of use.  Just a few capsules per ...
... SAN DIEGO, Sept. 29, 2011 Awarepoint ... system (RTLS) solutions for healthcare, announced today that ... (RFID) and RTLS Healthcare Competitive Strategy Leadership ... pioneering and providing complete RTLS and workflow automation ...
Cached Medicine Technology:Beverly Hills Secret Now Helping People Across The Country 2Awarepoint Corporation Receives Frost & Sullivan's 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award 2Awarepoint Corporation Receives Frost & Sullivan's 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award 3
(Date:7/29/2014)... -- Although the bite of a brown recluse spider ... alone, an expert notes. It,s still important to ... a brown recluse spider bite, warned Dr. Donna Seger, ... these potentially dangerous bites are on the rise. ... nothing. The [bite] has classic characteristics, but if physicians ...
(Date:7/29/2014)... Using quality improvement measures in eight of the ... Study Group, researchers have found a way to reduce ... dye. , Currently, 7-15 percent of these patients who ... with kidney injury, which can result in death or ... permanent dialysis, says a study published in the July ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis ... D by a projected $2.9 to $5.8 billion next ... firm Milliman released today by the Pharmaceutical Care Management ... could increase by as much as 8.6 percent in ... including Sovaldi and Olysio. , The study finds that ...
(Date:7/29/2014)... Alto, CA (PRWEB) July 29, 2014 ... and well-being in older adults. Once again, the non-profit agency ... Celebration, a free event for seniors. , This event gives ... active and maintain better health. There will be a variety ... and dancing, wellness vendors, tech demonstrations and artists. In addition, ...
(Date:7/29/2014)... donor kidney transplants receive steady follow-up care, the ... To make follow-up care more accessible, UC San ... collaborating to launch the first program in the ... charge to living kidney donors. , UCSF will ... more than 4,500 Walgreens pharmacies and Healthcare Clinic ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Caring for donors 2Health News:Caring for donors 3
... Web site,s c ontent is ... CHICAGO, July 15 In an emergency, immediate access to ... death. Personal health records (PHRs) often help ease the tension and ... encounters. To increase its PHR public outreach, the American Health Information ...
... , Goodman: Bill Contains All the Bad ... DALLAS, July 15 The Democrats, health care reform bill currently ... health plan that will undercut the private market and force as many ... forced into a Medicare-like plan, according to National Center for Policy Analysis ...
... , Dr. Thomas Bryant Brings Hill ... WASHINGTON, July 15 The National Coalition of Mental ... Bryant, MD, JD, as its first-ever Director of Government Relations. Dr. ... excited to join the staff of the National Coalition. The most ...
... HMSY ) today announced it will host a webcast and conference call at 9:00 am ET on ... which ended June 30. Financial results are scheduled for release before the market opens on Friday, ... William Lucia, CEO, Walter Hosp, CFO, ... 9:00 AM ET, , , HOW: Presentation: , ...
... , , American Society of ... s Water and Wastewater Infrastructure Systems , ... owe our health and much of our quality of life to the ... water and wastewater systems on which we rely. Despite the importance of ...
... , BETHESDA, Md., July 15 ... solutions, today announced the release of the PatientLife System(R) 3.5 (PLS ... focused on accelerating the discharge planning process and reducing average length ... , "We are excited about the new functionality of ...
Cached Medicine News:Health News:AHIMA Launches New Interactive myPHR.com Web Site 2Health News:AHIMA Launches New Interactive myPHR.com Web Site 3Health News:House Democrat's Health Care Reform Bill Is a 1,018-Page Nightmare 2Health News:National Coalition of Mental Health Consumer/Survivor Organizations Hires Director of Government Relations 2Health News:HMS Holdings Corp. Hosts Second Quarter 2009 Financial Teleconference and Presentation 2Health News:Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 2Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 2Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 3Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 4
BD Visitec IOL Manipulator (Sinskey), blunt tip angled 45, 15.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles han...
... BD Visitec IOL Manipulator (Jaffe-Maltzman), ... mm from end, fits 0.20 ... for positioning intraocular lenses, (3/bx, ... intraocular lenses. Sure grip handles ...
Maltzman-Fenzl lens manipulator, V shaped tip, straight. Also available in titanium....
Sinskey lens manipulator, straight. Also available in titanium....
Medicine Products: